Track topics on Twitter Track topics that are important to you
PharmaMar S.A. (Madrid:PHM) submitted an MAA to EMA for Aplidin plitidepsin in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM). In March, the company said the candidate significantly improved progression-free survival (PFS) in the Phase III ADMYRE study to treat MM, meeting the trial's primary endpoint (see BioCentury Extra, March 31).
Aplidin is a marine-derived VEGF inhibitor. In 2014, PharmaMar granted Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) rights to the candidate in eight EU countries, including the U.K. The MAA submission triggers a EUR 4 million ($4.5 million) payment to PharmaMar from Chugai.
PharmaMar gained EUR 0.07 to EUR 2.85 on Thursday.
Original Article: PharmaMar submits Aplidin MAANEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...